Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
Completed
Daiichi Sankyo Inc.
Phase 3
2009-10-01
Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing
recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the
legs and/or blood clots in the lungs.
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
Completed
Daiichi Sankyo, Inc.
Phase 3
2009-10-01
Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing
recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the
legs and/or blood clots in the lungs.
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
Completed
Daiichi Sankyo Inc.
Phase 2
2012-08-01
Assess the relative change in thrombus volume as determined by two assessments (Baseline and
Day 14-21) with magnetic resonance venography (MRV) in subjects with deep-vein thrombosis
(DVT) treated with either an edoxaban monotherapy regimen or a low molecular weight (LMW)
heparin/warfarin regimen.
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
Completed
Daiichi Sankyo, Inc.
Phase 2
2012-08-01
Assess the relative change in thrombus volume as determined by two assessments (Baseline and
Day 14-21) with magnetic resonance venography (MRV) in subjects with deep-vein thrombosis
(DVT) treated with either an edoxaban monotherapy regimen or a low molecular weight (LMW)
heparin/warfarin regimen.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
